IL6 and neoplasm: Therefore, targeting the IL-6/JAK/STAT3 pathway in patients with ONB might provide therapeutic benefit by directly suppressing tumor cell proliferation and restoring antitumor immunity, as already demonstrated in several other histotypes [21].